In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Targa Therapies SA

Executive Summary

Targa Therapies marries gene therapy and monoclonal antibodies in its proprietary Antibody Delivery System, which it believes will help circumvent many of the flaws in current gene therapies.

You may also be interested in...

Protiva Biotherapeutics Inc.

Protiva Biotherapeutics is using liposomes to deliver plasmids, or pieces of DNA. The liposome cover does two things; it protects the plasmid from being quickly degraded in the circulation. And it improves targeting to tumors, since liposomes gather preferentially at sites of vascular leakage--generally the disorganized vasculatures of tumors.

Antiviral Sentiment

The alarm bell is ringing for companies developing adenoviral vectors for gene therapies, particularly those meant to treat liver disease. But every firm in the field is now on alert.

Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts